• August 4, 2020

Genprex to Present at Proactive’s One2One Virtual Investor Forum on August 4, 2020 - Odessa American: Business

e-Edition Subscribe

Genprex to Present at Proactive’s One2One Virtual Investor Forum on August 4, 2020

Print
Font Size:
Default font size
Larger font size

Posted: Friday, July 31, 2020 7:17 am | Updated: 7:46 am, Fri Jul 31, 2020.

AUSTIN, Texas--(BUSINESS WIRE)--Jul 31, 2020--

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced today that the Company will present at the Proactive Investors One2One Virtual Event on August 4, 2020.

Mr. Rodney Varner, Genprex’s Chairman and Chief Executive Officer, will deliver a Company overview and provide updates on its product pipeline, including its lead drug candidate, GPX-001 (formerly referred to as “Oncoprex™” immunogene therapy), which received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for use in combination with AstraZeneca’s Tagrisso ® in late stage lung cancer patients with EGFR mutations whose tumors progress on Tagrisso. Mr. Varner will also provide an overview of the Company’s preclinical diabetes gene therapy candidate that may have the potential to cure Type 1 and Type 2 diabetes.

Event: Proactive Investors One2One Virtual Event

Date: Tuesday, August 4, 2020

Time: 1:40 p.m. ET

Registration Link:https://bit.ly/2D3fpx7

The Proactive Investor One2One investor forums are designed for private investors, private client brokers, fund managers, financial institutions, hedge funds, buy and sell side analysts and journalists.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso ® ) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone . For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of GPX-001, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of GPX-001 and our other potential product candidates including whether we receive fast track or similar regulatory designations; costs associated with developing our product candidates and whether patents will ever be issued under patent applications that are the subject of our license agreements. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200731005061/en/

CONTACT: Genprex, Inc.

(877) 774-GNPX (4679)Investor Relations

GNPX Investor Relations

(877) 774-GNPX (4679) ext. #2

investors@genprex.comMedia Contact

Genprex Media Relations

Kalyn Dabbs

(877) 774-GNPX (4679) ext. #3

media@genprex.com

KEYWORD: TEXAS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: RESEARCH TECHNOLOGY DIABETES OTHER TECHNOLOGY BIOTECHNOLOGY PHARMACEUTICAL HEALTH SCIENCE ONCOLOGY OTHER SCIENCE

SOURCE: Genprex, Inc.

Copyright Business Wire 2020.

PUB: 07/31/2020 08:17 AM/DISC: 07/31/2020 08:17 AM

http://www.businesswire.com/news/home/20200731005061/en

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Clear
70°
Humidity: 67%
Winds: SE at 3mph
Feels Like: 70°

Your Extended Forecast

Tomorrow

weather
High 102°/Low 75°
Mainly sunny. Highs 100 to 104F and lows in the mid 70s.

wednesday

weather
High 103°/Low 75°
More sun than clouds. Highs 101 to 105F and lows in the mid 70s.

thursday

weather
High 102°/Low 74°
More sun than clouds. Highs 100 to 104F and lows in the mid 70s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.